Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes

Kanayama, Shoji; Okamoto, Kyoichi; Ikeda, Fumiaki; Ishii, Ritsuko; Matsumoto, Takuya; Hayashi, Noritaka; Gotoh, Naomasa

doi:10.1016/j.jiac.2017.03.004

Cited by 7 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levofloxacin‐resistant strains were isolated during 2019 to 2020 from three patients, of which two had used topical nadifloxacin and the other had used oral levofloxacin for acne treatment. The Japanese acne treatment guidelines recommend topical use of nadifloxacin and ozenoxacin, and the emergence frequency of resistant strains at exposure concentrations is quite low after adequate use 24–26 . Hence, we presume inappropriate use of topical quinolones by some patients.…”

Section: Discussionmentioning

confidence: 97%

Increased frequency of clindamycin‐resistant Cutibacterium acnes strains isolated from Japanese patients with acne vulgaris caused by the prevalence of exogenous resistance genes

Koyanagi

Koizumi

Nakase

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Cutibacterium acnes, a resident bacterium of the skin, is a target for antimicrobial treatment of acne vulgaris, because it exacerbates inflammation. Recently, antimicrobialresistant C. acnes strains have been isolated worldwide, and their prevalence has led to failure of antimicrobial treatment. This study aimed to analyze the antimicrobial resistance of C. acnes strains isolated from Japanese patients with acne vulgaris who visited the

show abstract

Section: Discussionmentioning

confidence: 97%

Increased frequency of clindamycin‐resistant Cutibacterium acnes strains isolated from Japanese patients with acne vulgaris caused by the prevalence of exogenous resistance genes

Koyanagi

Koizumi

Nakase

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Another Japanese study showed that MICs of ozenoxacin against three levofloxacin-susceptible Propionibacterium acnes strains (MIC of levofloxacin; ≤4 μg/ml) and three levofloxacin-resistant P. acnes strains (MIC of levofloxacin; ≥8 μg/ml) ranged from 0.03 to 0.06 μg/ml and from 0.25 to 0.5 μg/ml, respectively [33]. These results suggest that ozenoxacin has a potent bactericidal activity against both levofloxacin-susceptible and levofloxacin-resistant P. acnes, a microorganism not included in the present study.…”

Section: Discussionmentioning

confidence: 99%

Microbiological Profile of Ozenoxacin

Morrissey¹,

Vilà

Gargallo-Viola³

et al. 2019

Future Microbiol.

View full text Add to dashboard Cite

To explore the antibacterial spectrum of ozenoxacin and compare its in vitro activity with that of other antibacterial agents. Materials & methods: In 2010, 10,054 isolates were collected from 128 centers worldwide. Minimum inhibitory concentrations against Gram-positive and Gram-negative isolates were determined for 23 and 13 antibacterial agents, respectively. Results: Ozenoxacin exhibited high in vitro activity against susceptible, and methicillin-or levofloxacin-resistant, Gram-positive bacteria. Ozenoxacin was one or two dilutions less active against Enterobacteriaceae isolates, except for Escherichia coli, than other quinolones. Conclusion: Ozenoxacin is a potent antimicrobial agent mainly against susceptible and resistant strains of Gram-positive isolates (staphylococci and streptococci), and shows activity against some Gram-negative isolates.

show abstract

“…The minimum inhibitory concentration (MIC) test systems were created by diluting different drug solution in 96-well plates to a volume of 100 μL, and the enrofloxacin sodium, enrofloxacin hydrochloride and EM were double diluted 28 to final concentrations ranging from 25 to 0.0488 μg/mL, and then 100 μL bacterial suspensions was added to each drug-containing well. The MIC was determined visually as the first dilution step with a complete growth inhibition [30][31][32] and the minimum bactericidal concentration (MBC) was determined after the MIC. 10 μL mixtures were extracted from the wells in the 96-well plate that were visually free of bacterial growth, and then uniformly coated on the MHA medium after serial dilution, and incubated at 37°C for 18-24 h. The number of colonies on the plate was calculated, and the minimum concentration killing 99.9% of the bacteria was recorded as MBC.…”

Section: The Antibacterial Activity In Vitromentioning

confidence: 99%

“…10 μL mixtures were extracted from the wells in the 96-well plate that were visually free of bacterial growth, and then uniformly coated on the MHA medium after serial dilution, and incubated at 37°C for 18-24 h. The number of colonies on the plate was calculated, and the minimum concentration killing 99.9% of the bacteria was recorded as MBC. [30][31][32] The MIC and MBC of standard strains and clinical strains of Escherichia coli, Salmonella and Staphylococcus aureus were determined.…”

Section: The Antibacterial Activity In Vitromentioning

confidence: 99%

<p>Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate</p>

Pei

Yang

et al. 2020

DDDT

View full text Add to dashboard Cite

Introduction: Enrofloxacin is used in the treatment of a wide variety of bacterial infections in mammals. However, its poor solubility limits the clinical use. Methods: In order to improve the solubility of enrofloxacin, the enrofloxacin mesylate (EM) were obtained by a chemical synthesis method. The characterization of EM was carried out using ultraviolet scan (UV), synchronous thermal analysis (SDT), fourier transform infrared spectrometer (FTIR) and mass spectrometry (MS), nuclear magnetic resonance (NMR) and X-ray powder diffraction analysis (XRPD). Acute toxicity of EM in Kunming mice was studied. Besides, pharmacokinetic studies were performed in New Zealand rabbits at a single oral dose of 10 mg/kg, and the antibacterial activity of EM was also evaluated. Results: EM was successfully synthesized and purified. The stoichiometric ratio of mesylate to enrofloxacin was 1:1 and the aqueous solubility of EM was 483.01±4.06 mg/mL, the solubility of EM was about 2000 times higher than enrofloxacin. The oral lethal dose (LD 50 ) of EM was 1168.364 mg/kg, and the pharmacokinetics indicated that the oral relative bioavailability of EM was about 1.79 times and 1.48 times higher than that of enrofloxacin and enrofloxacin hydrochloride, respectively. In addition, the in vitro antibacterial activity of EM was not significantly changed compared with enrofloxacin and enrofloxacin hydrochloride. Conclusion: EM has higher solubility, low toxicity for oral use, and increases the oral bioavailability in rabbit. This study may be of benefit for the development of new enrofloxacin drugs.

show abstract

Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes

Cited by 7 publications

References 29 publications

Increased frequency of clindamycin‐resistant Cutibacterium acnes strains isolated from Japanese patients with acne vulgaris caused by the prevalence of exogenous resistance genes

Increased frequency of clindamycin‐resistant Cutibacterium acnes strains isolated from Japanese patients with acne vulgaris caused by the prevalence of exogenous resistance genes

Microbiological Profile of Ozenoxacin

<p>Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate</p>

Contact Info

Product

Resources

About